Showing results (101-110 of 153) with videos related to

Sort By:
Pageof 16
JAMA Internal Medicine|October 1, 2020
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical TrialBenjamin S Abella, Eliana L Jolkovsky, Barbara T Biney, et al.
AIDS (London, England)|April 8, 2021
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxisRogers Sekabira, Ian McGowan, Krista Yuhas, et al.
The Lancet. HIV|May 27, 2017
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trialMartin Markowitz, Ian Frank, Robert M Grant, et al.
Vaccine|March 19, 2023
Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trialGregory J Wilson, Benigno Rodriguez, Shuying Sue Li, et al.
The New England Journal of Medicine|March 7, 2014
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIVPablo Tebas, David Stein, Winson W Tang, et al.
Nature Communications|November 28, 2024
Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosaMaria P Lemos, Rena D Astronomo, Yunda Huang, et al.
Plos One|September 21, 2018
Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trialMarnie L Elizaga, Shuying S Li, Nidhi K Kochar, et al.
Ebiomedicine|February 2, 2024
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trialMaurine D Miner, Allan deCamp, Nicole Grunenberg, et al.
Plos Medicine|November 15, 2017
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H Mayer, Kelly E Seaton, Yunda Huang, et al.
JCI Insight|May 10, 2022
A phase I trial of cyclosporine for hospitalized patients with COVID-19Emily A Blumberg, Julia Han Noll, Pablo Tebas, et al.
Pageof 16